<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196728</url>
  </required_header>
  <id_info>
    <org_study_id>CellMed CM3.1-AC100/03</org_study_id>
    <secondary_id>2010-020895-49</secondary_id>
    <nct_id>NCT01196728</nct_id>
  </id_info>
  <brief_title>Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes</brief_title>
  <official_title>Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellMed AG, a subsidiary of BTG plc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellMed AG, a subsidiary of BTG plc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of the
      Glucagon-like peptide-1 (GLP-1) peptide analogue CM3.1-AC100 after single subcutaneous (sc)
      doses in patients with T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measurements</measure>
    <time_frame>Safety will be monitored continously and safety assessments will be made on several occasions throughout the whole study</time_frame>
    <description>AEs, ECGs, BP, pulse, body temperature, laboratory variables, local tolerability including a VAS score for local pain, Present Nausea Intensity (PNI) by a nausea questionnaire and a VAS score of the Overall Nausea Index (ONI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK samples for CM3.1-AC100</measure>
    <time_frame>Intense PK-sampling during the 24 hours following administration of CM3.1-AC100</time_frame>
    <description>Pharmacokinetics:
AUC, AUC0-4h, AUC0-t, Cmax, tmax, t1/2lz, λz, CL/F, Vz/F of CM3.1-AC100</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CM3.1-AC100 dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound CM3.1-AC100 s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM3.1-AC100 dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound CM3.1-AC100 s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CM3.1-AC100 dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound CM3.1-AC100 s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for compound CM3.1-AC100 s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CM3.1-AC100</intervention_name>
    <description>SAD study with single ascending subcutaneous doses</description>
    <arm_group_label>CM3.1-AC100 dose A</arm_group_label>
    <arm_group_label>CM3.1-AC100 dose B</arm_group_label>
    <arm_group_label>CM3.1-AC100 dose C</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent prior to any study specific procedures

          2. Type 2 diabetes mellitus patient, diagnostically confirmed since at least 6 months

          3. Male or female patient aged 18 to 75 years at screening, both inclusive

          4. BMI &gt;22 to ≤40 kg/m2 at screening

        Exclusion Criteria:

          1. Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary
             forms of diabetes, eg Cushings's syndrome and acromegaly

          2. Fasting C-peptide &lt; 500 pM at screening

          3. Acute gastrointestinal symptoms at the time of screening and/or Day -1

          4. Any clinically relevant history or the presence of cardiovascular, bronchopulmonary,
             gastrointestinal or neurological diseases inclusive history of chronic pancreatitis or
             acute pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Geigle, Dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>CellMed AG, a subsidiary of BTG plc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>December 3, 2010</last_update_submitted>
  <last_update_submitted_qc>December 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Peter Geigle</name_title>
    <organization>Cellmed AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

